Alert: Rating Upgrade (8/31/18)-BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).

out_logo_500#23547.jpg

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX)

ALERT – STOCK RATING UPGRADE

out_mm#23547.jpg

Stock Rating Upgrade

Of late the Value Trend Rating for BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) improved from D to C reflecting improving fundamentals and high Appreciation Potential.

Recent Price Action

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock closed at $7.16 on 8/31/18 after being unchanged was unchanged. However, this flat performance was accompanied by exceptionally low trading volume at 49% of normal. The stock has declined -0.8% during the last week but has been exceptionally strong relative to the market over the last nine months.

Current PriceTarget Research Rating

BCRX’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a major Value Eraser.

BCRX has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. BCRX has a very high Power Rating of 86 but a very low Appreciation Score of 6, producing the Low Neutral Value Trend Rating.

About John Lafferty 91533 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.